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Introduction
The management of juvenile idiopathic arthritis (JIA)
has been revolutionised through biologics such as eta-
nercept (ETN), approved in the UK in 2002. Since that
time, the use of other biologics in children and young
people (CYP) has expanded. ETN is most often the first
choice biologic in the treatment of JIA; however there
may be occasions where ETN is not the preferred
choice, for reasons of efficacy or safety.
Objectives
The aim of this analysis was to describe the choice of first-
line biologics in UK CYP with JIA and explore possible
reasons behind this choice.
Methods
Both the British Society for Paediatric and Adolescent
Rheumatology Etanercept Cohort Study (BSPAR-ETN),
and the Biologics for Children with Rheumatic Diseases
(BCRD) study, are ongoing prospective observational
cohorts, collecting detailed information on CYP starting
biologics for JIA. At start of therapy, demographic and
disease information is collected. Patients registered from
01/01/2010 starting a first biologic were compared
between therapies using descriptive statistics. CYP
starting ETN <2010 were also included to analyse
changes in ETN prescribing since initial approval.
Results
To 07/04/2014, 870 patients were recruited starting a first-
line biologic (123 BCRD; 747 BSPAR-ETN (582<2010,
165≥2010) (Table 1). From 2010, CYP with systemic JIA
(sJIA) were almost exclusively prescribed anakinra or toci-
lizumab. Choice of anti-TNF therapy was largely driven by
prevalence of uveitis. Compared to ETN patients pre-
2010, CYP starting ETN from 2010 had shorter disease
duration, less uveitis, less sJIA, and less corticosteroid use.
Conclusion
Although ETN remains the most common biologic pre-
scribed for JIA, there has been a shift towards the use of
alternative biologics, some unlicensed, largely driven by
disease subtype and the presence of uveitis. This chan-
nelling of certain children towards specific therapies is
important in terms of future comparative effectiveness




1Arthritis Research UK Centre for Epidemiology, Manchester Academic Health
Science Centre, The University of Manchester, Manchester, UK
Full list of author information is available at the end of the article
Davies et al. Pediatric Rheumatology 2014, 12(Suppl 1):P190
http://www.ped-rheum.com/content/12/S1/P190
© 2014 Davies et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1Arthritis Research UK Centre for Epidemiology, Manchester Academic Health
Science Centre, The University of Manchester, Manchester, UK. 2Hey
Children’s Foundation NHS Trust, Liverpool, UK. 3Institue of Translational
Medicine (Child Health), University of Liverpool, Liverpool, UK.
4Musculoskeletal Research Group, Institute Cellular Medicine, Newcastle
University, Newcastle upon Tyne, UK. 5Department of Paediatric
Rheumatology, Institute of Child Health, Birmingham Children’s Hospital –
NHS Trust and University of Birmingham, Birmingham, UK.
Published: 17 September 2014
doi:10.1186/1546-0096-12-S1-P190
Cite this article as: Davies et al.: Factors associated with choice of first
biologic among children with juvenile idiopathic arthritis: a combined
analysis from two UK paediatric biologic registers. Pediatric
Rheumatology 2014 12(Suppl 1):P190.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Table 1
Biologic start post 01/01/2010, unless specified.













Female 109 (67%) 30 (67%) 17 (59%) 14 (44%) 11 (73%) 384 (66%)
Age, years 11 (8, 14) 10 (6, 14) 8 (5, 10) 8 (4, 11) 3 (2, 13) 11 (8, 14)
Disease duration, years 2 (1, 5) 4 (2, 6) 3 (2, 6) 1 (1, 2) 0 (0, 1) 4 (2, 7)
ILAR Category
Systemic arthritis 5 (3%) 1 (2%) 1 (3%) 28 (88%) 15 70 (12%)
Oligoarthritis 39 (24%) 24 (53%) 16 (55%) 0 (100%) 117 (20%)
Polyarthritis 83 (50%) 9 (20%) 9 (31%) 3 (9%) 0 253 (43%)
Enthesitis Related Arthritis 10 (6%) 5 (11%) 2 (7%) 0 0 50 (9%)
Psoriatic arthritis 10 (6%) 5 (11%) 1 (3%) 0 0 44 (8%)
Other 18 (11%) 1 (2%) 0 1 (3%) 0 48 (8%)
0
Concomitant MTX 77 (47%) 31 (69%) 26 (90%) 28 (88%) 12 (80%) 322 (55%)
Concomitant corticosteroids 15 (9%) 7 (16%) 5 (17%) 23 (72%) 7 (47%) 146 (25%)
Ever had uveitis 7 (5%) 31 (70%) 21 (72%) 0 0 54 (11%)
CHAQ [0-3] 1 (0, 2) 1 (0, 1) 0 (0, 1) 1 (0, 2) 2 (1, 2) 1 (0, 2)
JADAS-71 13 (8, 21) 10 (7, 17) 6 (3, 12) 19 (1, 22) 23 (7, 30) 16 (9, 23)
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